Cargando…

Letter re: ‘Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications’

Detalles Bibliográficos
Autores principales:	Sullivan, W.G., Hatswell, A.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710459/ https://www.ncbi.nlm.nih.gov/pubmed/34924145 http://dx.doi.org/10.1016/j.esmoop.2021.100282

Ejemplares similares

Response to comment on “Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications”
por: Krebs, M.G., et al.
Publicado: (2021)

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
por: Krebs, M.G., et al.
Publicado: (2021)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
por: Ardini, Elena, et al.
Publicado: (2020)

Reply to ‘Comment on “Tumour-agnostic drugs in paediatric cancers”’
por: Chisholm, Julia C., et al.
Publicado: (2020)

Comment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020
por: Oliver, Thomas Richard William, et al.
Publicado: (2020)

Entrectinib for non-small cell lung cancer and solid tumours
Publicado: (2020)

Tumour-agnostic drugs in paediatric cancers
por: Chisholm, Julia C., et al.
Publicado: (2020)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Drug Development in Tissue-Agnostic Indications
por: du Rusquec, Pauline, et al.
Publicado: (2021)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity
por: Deger, Teoman, et al.
Publicado: (2022)

Letter to the Editor: Re: Comparison of IVF-ET outcomes in patients with hydrosalpinx pretreated with either sclerotherapy or laparoscopic salpingectomy
por: Shokeir, Tarek
Publicado: (2014)

Letter Re: Butyrylcholinesterase is a potential biomarker for sudden infant death syndrome
por: Harrington, Carmel Therese, et al.
Publicado: (2022)

Reply to the letter from Professor Hardell
por: Smith, J.G., et al.
Publicado: (1993)

Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer
por: Kato, Shunsuke
Publicado: (2021)

Population genomics of intrapatient HIV-1 evolution
por: Zanini, Fabio, et al.
Publicado: (2015)

Intrapatient competition of VEXAS syndrome and CML clones
por: Djerbi, Nadia, et al.
Publicado: (2023)

Letter to the Editor. Re: Lateralization of Cognitive Functions in Aphasia after Right Brain Damage
por: Derakhshan, Iraj
Publicado: (2013)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022)

Re: Orthognathic surgery in COVID-19 times, is it safe?
por: Gibbons, A.J., et al.
Publicado: (2021)

Development of Neuropathic Arthropathy With Entrectinib: Case Report
por: Giustini, Nicholas P., et al.
Publicado: (2022)

The Bacillus Agnostic
Publicado: (1911)

Letter to the Editor: There Is No Indication for Treating Long COVID Vaccination Syndrome With Colchicine
por: Finsterer, Josef
Publicado: (2022)

Intrapatient Comparison of Coblation versus Electrocautery Tonsillectomy in Children: A Randomized, Controlled Trial
por: Choi, Kyu Young, et al.
Publicado: (2022)

Evidence of Recombination in Intrapatient Populations of Hepatitis C Virus
por: Sentandreu, Vicente, et al.
Publicado: (2008)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
por: Grogan, Patrick T, et al.
Publicado: (2022)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

Re: Letter to the Editor re: Dror and Kukucka, Linear Sequential Unmasking–Expanded (LSU-E): A general approach for improving decision making as well as minimizing noise and bias
por: Freeman, Michael, et al.
Publicado: (2021)

Agnostic Tendency in Doctors
Publicado: (1885)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Long-term intrapatient evolution during HIV-2 infection
por: MacNeil, Adam, et al.
Publicado: (2006)

CancerTracer: a curated database for intrapatient tumor heterogeneity
por: Wang, Chen, et al.
Publicado: (2020)

Evaluation of capillary density in psoriasis: An intrapatient study and literature review
por: Micali, Giuseppe, et al.
Publicado: (2021)

Intrapatient variability of 18F-FDG uptake in normal tissues
por: Sayed, Mohamed Hosny Mohamed, et al.
Publicado: (2022)

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
por: Garcia-Foncillas, Jesus, et al.
Publicado: (2022)

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
por: Meneses-Lorente, Georgina, et al.
Publicado: (2023)

Letter to the editor of Heliyon re: new considerations on the validity of the Wiener-Granger causality test [Heliyon 6(10) (2020) e05208]
por: Grassmann, Greta
Publicado: (2021)

Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report
por: Taban, Hakan, et al.
Publicado: (2022)

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dafkmadciciqhk5sc0s6ponmja